-
公开(公告)号：US11566073B2
公开(公告)日：2023-01-31
申请号：US16617725
申请日：2018-06-01
Applicant: Bristol-Myers Squibb Company
Inventor： Robin Edwards , William J. Geese , Danielle M. Greenawalt
Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
-
公开(公告)号：US20230119066A1
公开(公告)日：2023-04-20
申请号：US17914257
申请日：2021-03-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Ruth Yin-Zong Lan , Olufemi A. Adelakun , Ishita Barman , Joseph Campbell , SJ Jian Zhe Diong , Felix Findeisen , Danielle M. Greenawalt , Renu Jain , Amy D. Jhatakia , John K. Lee , Peter S.K. Lee , Linda Liang , Kai Lu , Bryan McDonald , Paul Mesko , Arvind Rajpal , Sharmila Sambanthamoorthy , Mark J. Selby , Nathan O. Siemers , Pavel Strop , Gaby A. Terracina , Xi-Tao Wang
Abstract: This disclosure provides isolated antibodies, for example, monoclonal antibodies, that specifically bind to the C-C Motif Chemokine Receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by anti-body-dependent cellular cytotoxicity (ADCC). The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CCR8 antibody as monotherapy or in combination with an anti-cancer agent such as an immune checkpoint inhibitor, for example, an anti-PD-1 or anti-PD-L1 antibody.
-
公开(公告)号：US12227576B2
公开(公告)日：2025-02-18
申请号：US18161713
申请日：2023-01-30
Applicant: Bristol-Myers Squibb Company
Inventor： Robin Edwards , William J. Geese , Danielle M. Greenawalt
Abstract: This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity. In some embodiments, the tumor is derived from a non-small cell lung cancer (NSCLC). In some embodiments, the tumor expresses Programmed Death Ligand 1. In some embodiments, the subject carries a wild-type STK11 gene.
-
-
Search Results
3
records
(took 0.012 seconds)
